Clinical Chemistry Siemens Point of Care - Urinalysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 2036-2042, 2006. First published September 21, 2006; 10.1373/clinchem.2006.074724
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2006.074724v1
52/11/2036    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhu, S.
Right arrow Articles by Meng, Q. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhu, S.
Right arrow Articles by Meng, Q. H.
Related Collections
Right arrow General Clinical Chemistry
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Hemostasis and Thrombosis
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2006;52:2036-2042.)
© 2006 American Association for Clinical Chemistry, Inc.

Lipids, Lipoproteins, and Cardiovascular Risk Factors

Inhibitory Effects of Micronized Fenofibrate on Carotid Atherosclerosis in Patients with Essential Hypertension

Shiming Zhu1,2, Guohai Su2 and Qing H. Meng1,a

1 Department of Pathology and Laboratory Medicine, Royal University Hospital, College of Medicine, University of Saskatchewan, Saskatoon, Canada.
2 Department of Medicine, Clinical Medical College of Shandong University, Jinan, China.

aAddress correspondence to this author at: Department of Pathology and Laboratory Medicine, Room 4917, Royal University Hospital, University of Saskatchewan, 103 Hospital Drive, Saskatoon, SK, S7N 0W8 Canada. Fax 306-655-2193; e-mail qing.meng{at}usask.ca.

Background: The coexistence of hypertension and dyslipidemia synergistically increases the risk of cardiovascular events. We investigated the effect of the lipid-lowering agent micronized fenofibrate on inhibition of carotid atherosclerosis in patients with essential hypertension and mild hyperlipidemia.

Methods: We measured serum lipid profiles and inflammatory markers on chemistry or immune analyzers and common or internal carotid intima-media thickness (IMT) and diameter (D) by ultrasonography.

Results: Patients receiving micronized fenofibrate for 24 months in addition to antihypertensive treatment had decreased concentrations of total cholesterol, LDL-cholesterol, triglyceride, apolipoprotein B100, oxidized LDL, high-sensitivity C-reactive protein, P-selectin, and cytokines. These patients had increased concentrations of HDL-cholesterol, apolipoprotein A-I, and nitric oxide. Common carotid artery IMT (CCAIMT) and internal carotid artery IMT (ICAIMT) remained unchanged during the 24-month intervention. Moreover, the mean CCAIMT/D ratio and ICAIMT/D ratio were significantly decreased in the fenofibrate intervention group. In contrast, CCAIMT/D and ICAIMT/D ratios were increased in the control group. The incidence rates of carotid artery plaque formation and stroke in the fenofibrate intervention group were significantly lower than those in the control group.

Conclusion: The combination of antihypertensive agents with micronized fenofibrate can effectively prevent the progression of carotid atherosclerosis and reduce the incidence of stroke in patients with essential hypertension.




The following articles in journals at HighWire Press have cited this article:


Home page
 J Am Coll CardiolHome page
A. Hiukka, J. Westerbacka, E. S. Leinonen, H. Watanabe, O. Wiklund, L. M. Hulten, J. T. Salonen, T.-P. Tuomainen, H. Yki-Jarvinen, A. C. Keech, et al.
Long-Term Effects of Fenofibrate on Carotid Intima-Media Thickness and Augmentation Index in Subjects With Type 2 Diabetes Mellitus
J. Am. Coll. Cardiol., December 16, 2008; 52(25): 2190 - 2197.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes and Vascular Disease ResearchHome page
G. Steiner
Atherosclerosis in type 2 diabetes: a role for fibrate therapy?
Diabetes and Vascular Disease Research, December 1, 2007; 4(4): 368 - 374.
[Abstract] [PDF]

Home page
 J. Clin. Pathol.Home page
L. M Agius
Complicated atheromatous plaque as integral atherogenesis
J. Clin. Pathol., June 1, 2007; 60(6): 589 - 592.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.